Interpretation of 2023 AHA Scientific Statement:Cancer Therapy Related Hypertension / 医药导报
Herald of Medicine
; (12): 155-160, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1023692
Responsible library:
WPRO
ABSTRACT
In January 2023,the American Heart Association(AHA)released A Scientific StatementCancer Therapy Related Hypertension,provided an overview of the mechanisms and clinical management of anticancer therapy related hypertension.Contemporary anticancer drugs are mostly at the expense of cardiovascular toxicities,one of the most common side effects is hypertension,especially vascular endothelial growth factor inhibitors,as well as tyrosine kinase inhibitors and proteasome inhibitors.Cancer therapy related hypertension is often dose limiting,and is usually reversible after interruption or discontinuation of treatment.The exact molecular mechanisms underlying hypertension are unclear,recent discoveries indicate an important role for decreased nitric oxide,increased endothelin-1,endothelial dysfunction,increased sympathetic outflow,and microvascular rarefaction.Based on the International Cardio Oncology Society(IC-OS),this article provides an interpretation of the diagnosis and management of hypertension related to cancer treatment.Insufficient evidence exists supporting an antihypertensive medication strategy specific to patients with anticancer therapy induced hypertension,therefore,antihypertensive management should follow current guidelines for the general population..Multidisciplinary cooperation is needed to optimize management to ensure the optimal therapeutic effect from cancer treatment while minimizing competing cardiovascular toxicities.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Herald of Medicine
Year:
2024
Type:
Article